| Literature DB >> 32582610 |
Paulo J M Bispo1,2, Lawson Ung1,2, James Chodosh1,2, Michael S Gilmore1,2,3.
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is a common cause of severe and difficult to treat ocular infection. In this study, the population structure of 68 ocular MRSA isolates collected at Massachusetts Eye and Ear between January 2014 and June 2016 was assessed. By using a combination of multilocus sequence typing (MLST) analysis, SCCmec typing and detection of the panton-valentine leukocidin (PVL) gene, we found that the population structure of ocular MRSA is composed of lineages with community and hospital origins. As determined by eBURST analysis of MLST data, the ocular MRSA population consisted of 14 different sequence types (STs) that grouped within two predominant clonal complexes: CC8 (47.0%) and CC5 (41.2%). Most CC8 strains were ST8, harbored type IV SCCmec and were positive for the PVL-toxin (93.7%). The CC5 group was divided between strains carrying SCCmec type II (71.4%) and SCCmec type IV (28.6%). Remaining isolates grouped in 6 different clonal complexes with 3 isolates in CC6 and the other clonal complexes being represented by a single isolate. Interestingly, major MRSA CC5 and CC8 lineages were isolated from discrete ocular niches. Orbital and preseptal abscess/cellulitis were predominantly caused by CC8-SCCmec IV PVL-positive strains. In contrast, infections of the cornea, conjunctiva and lacrimal system were associated with the MDR CC5 lineage, particularly as causes of severe infectious keratitis. This niche specialization of MRSA is consistent with a model where CC8-SCCmec IV PVL-positive strains are better adapted to cause infections of the keratinized and soft adnexal eye tissues, whereas MDR CC5 appear to have greater ability in overcoming innate defense mechanisms of the wet epithelium of the ocular surface.Entities:
Keywords: MRSA; Molecular Epidemiology; Ocular infection; Tissue tropism; biogeography of infections
Mesh:
Year: 2020 PMID: 32582610 PMCID: PMC7283494 DOI: 10.3389/fpubh.2020.00204
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
Figure 1Go eBurst-based population structure of ocular MRSA strains (n = 68). Each ST is represented by a circle. Lines connect single-locus variants. The black circles represent clonal complex founders. Circles not connected represent singleton STs in this particular population structure.
SCCmec typing and PVL detection according to the clonal complex.
| CC8 (32) | IV | 31 (45.6) | 30 |
| V | 1 (1.5) | 1 | |
| CC5 (28) | II | 20 (29.4) | – |
| IV | 8 (11.7) | – | |
| CC6 (3) | IV | 3 (4.4) | – |
| CC1 (1) | IV | 1 (1.5) | 1 |
| CC15 (1) | II | 1 (1.5) | 1 |
| CC22 (1) | IV | 1 (1.5) | 1 |
| CC59 (1) | IV | 1 (1.5) | 1 |
| CC96 (1) | NT | 1 (1.5) | – |
Demographic and clinicopathologic data for patients with culture-positive MRSA ocular infections at MEE, 2014–2016 (n = 58).
| Age (years, median) | 68.05 | 35.4 | |
| Male | 6 (22.2) | 13 (43.4) | 0.16 |
| Female | 21 (77.8) | 17 (56.7) | |
| Caucasian | 22 (81.5) | 23 (76.7) | 0.75 |
| Non-Caucasian | 5 (18.5) | 7 (23.3) | |
| History of contact lens wear | 8 (29.6) | 5 (16.7) | 0.35 |
| History of eye trauma | 3 (11.1) | 4 (13.3) | 1 |
| Prior eye surgery | 18 (66.7) | 5 (16.7) | |
| Previous intraocular lens insertion | 12 (44.4) | 3 (10.0) | |
| Ocular surface disease | 9 (33.3) | 5 (16.7) | 0.22 |
| Dry eye syndrome | 4 (14.8) | 4 (13.3) | 1 |
| Atopic eye disease | 1 (3.7) | 1 (3.3) | 1 |
| Lid disease | 9 (33.3) | 6 (20.0) | 0.37 |
| Lacrimal system dysfunction | 5 (18.5) | 5 (16.7) | 1 |
| Glaucoma | 6 (22.2) | 1 (3.3) | |
| Glaucoma drainage device | 1 (3.7) | 0 (0) | 0.47 |
| Use of topical antibiotic at presentation | 15 (55.6) | 3 (10.0) | |
| Use of topical antibiotic within the last week preceding presentation | 13 (48.5) | 5 (16.7) | |
| Use of topical steroids at presentation | 11 (40.7) | 5 (16.7) | 0.08 |
| Use of topical steroids within the last week preceding presentation | 10 (37.0) | 5 (16.7) | 0.13 |
| Known inpatient hospital admission in the last 3 months | 4 (14.8) | 3 (10.0) | 0.7 |
| Admission for eye surgery in the last 3 months | 5 (18.5) | 2 (6.7) | 0.24 |
| Non-acute clinical care | 6 (22.22) | 1 (3.3) | |
| Healthcare worker | 4 (14.8) | 5 (16.7) | 1 |
Out of 68 isolates included, 66 patient records were reviewed. One patient had two separate MRSA episodes (caused by different clones) and for one patient the record was not available.
includes corneal degenerative disease, bullous keratopathy, exposure keratopathy, dry eye syndrome, atopy, Stevens-Johnson syndrome and toxic epidermal necrolysis.
including blepharitis, trichiasis, floppy eyelid syndrome, ectropion and entropion, and lagophthalmos.
including dacryocystitis and dacryoadenitis.
including day-only procedures and overnight stays.
includes long-term care residents, nursing home care, chronic ambulatory care.
includes professions in close working contact with patients (e.g., nursing and allied health).
Bold values are represent statistically significant.
Distribution of the main ocular MRSA clones across different infections.
| Abscess/Cellulitis | 27 | 1 | 22 | 4 | |
| Keratitis | 14 | 12 | 1 | 1 | |
| Conjunctivitis | 9 | 6 | 2 | 1 | 0.1300 |
| Lacrimal system | 8 | 5 | 2 | 1 | 0.2349 |
| Eyelids | 4 | – | 4 | – | – |
| Endopthalmitis | 2 | 2 | – | – | – |
| Miscellaneous | 4 | 2 | 1 | 1 | – |
Bold values are represent statistically significant.
Figure 2Antimicrobial susceptibility profile of the main ocular MRSA clonal complexes. (A) Frequency (%) of CC5 and CC8 strains resistant to additional non-beta-lactam antibiotic classes. (B) Resistance rates for common antibiotics representing 5 different classes. Statistical significance was determined using Fisher's exact test.
In vitro susceptibility profile for topically used fluorquinolones among ocular MRSA isolates according to the clonal group.
| Moxifloxacin | 2 | 35.5 | 32 | 100 | 64 | 62.5 |
| Levofloxacin | 8 | 35.5 | >256 | 100 | >256 | 62.5 |
| Ofloxacin | 16 | 38.7 | >256 | 100 | >256 | 62.5 |
| Ciprofloxacin | 32 | 42.0 | >256 | 100 | >256 | 62.5 |
includes intermediate resistant isolates.
Molecular typing and antimicrobial resistances of MRSA keratitis cases.
| 1 | 2014 | ST5 | CC5 | II | Negative | USA100 | OXA, CLIN, ERY, CIP, LEV, OFLX, MOX | 3 | Vigamox |
| 2 | 2014 | ST105 | CC5 | II | Negative | SLV of ST5 | OXA, CLIN, ERY, CIP, LEV, OFLX, MOX | 3 | None |
| 3 | 2014 | ST5 | CC5 | IV | Negative | USA800 | OXA | 1 | UKN |
| 4 | 2014 | ST5 | CC5 | II | Negative | USA100 | OXA, CLIN, ERY, CIP, LEV, OFLX, MOX | 0 | None |
| 5 | 2014 | ST5 | CC5 | II | Negative | USA100 | OXA, CLIN, ERY, CIP, LEV, OFLX, MOX | 2 | UKN |
| 6 | 2015 | ST5 | CC5 | IV | Negative | USA800 | OXA, CLIN, ERY, CIP, LEV, OFLX, MOX | 2 | Polytrim + Erythromycin |
| 7 | 2015 | ST5 | CC5 | II | Negative | USA100 | OXA, CLIN, ERY, CIP, LEV, OFLX, MOX | 1 | UKN |
| 8 | 2015 | ST5 | CC5 | II | Negative | USA100 | OXA, CLIN, ERY, CIP, LEV, OFLX, MOX | 3 | None |
| 9 | 2015 | ST96 | CC96 | NT | Negative | NA | OXA, ERY | 3 | None |
| 10 | 2015 | ST8 | CC8 | IV | Positive | USA300 | OXA, CLIN, ERY, CIP, LEV, OFLX, MOX | 2 | None |
| 11 | 2015 | ST105 | CC5 | II | Negative | SLV of ST5 | OXA, CLIN, ERY, CIP, LEV, OFLX, MOX | 2 | Eythromycin and Ofloxacin |
| 12 | 2016 | ST5 | CC5 | II | Negative | USA100 | OXA, CLIN, ERY, CIP, LEV, OFLX, MOX | 0 | Vigamox + Tobramycin |
| 13 | 2016 | ST3390 | CC5 | II | Negative | SLV of ST5 | OXA, CLIN, ERY, CIP, LEV, OFLX, MOX | 3 | Vigamox |
| 14 | 2016 | ST5 | CC5 | II | Negative | USA100 | OXA, CLIN, ERY, CIP, LEV, OFLX, MOX | 3 | None |
The “1, 2, 3-Rule,” originally conceived by Vital et al. (.